L-forms and urinary tract infections.
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D000906:Antibodies; D001424:Bacterial Infections; D001437:Bacteriuria / Q000382:microbiology; D002473:Cell Wall; D002648:Child; D003017:Clostridium tetani; D003165:Complement System Proteins; D004731:Endotoxins / Q000096:biosynthesis; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007740:L Forms / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D008247:Lysosomes; D010403:Penicillin Resistance; D011512:Proteus Infections / Q000188:drug therapy / Q000382:microbiology; D012008:Recurrence; D018805:Sepsis / Q000188:drug therapy; D013744:Tetanus Toxin / Q000096:biosynthesis; D014552:Urinary Tract Infections / Q000209:etiology*
D000906:Antibodies; D004731:Endotoxins; D013744:Tetanus Toxin; D004917:Erythromycin; D000667:Ampicillin; D003165:Complement System Proteins